Drug intelligence / Profile preview

recombinant human anti-tetanus toxin monoclonal antibody (Lanzhou Institute)

Development stage: Unknown
Lead developer: Lanzhou Institute of Biological Products
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

Recombinant human anti-tetanus toxin monoclonal antibody is a biologic therapeutic developed by the Lanzhou Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG). This recombinant human IgG monoclonal antibody is designed to specifically bind and neutralize the tetanus toxin produced by *Clostridium tetani*, the causative agent of tetanus. It is being developed for both the prevention and treatment of tetanus, serving as a modern, standardized alternative to traditional plasma-derived human tetanus immunoglobulin (HTIG). By utilizing recombinant DNA technology, the product avoids the risks of blood-borne infection associated with human plasma and ensures consistent potency and quality across production batches. The drug has undergone Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetic profile in healthy adult volunteers.

Other names: recombinant human anti-tetanus toxin monoclonal antibody injection

Beyond the preview

Go deeper on recombinant human anti-tetanus toxin monoclonal antibody (Lanzhou Institute).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human anti-tetanus toxin monoclonal antibody (Lanzhou Institute).

Explore the full profile